We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDivi's Laboratories Limited

Divi's Laboratories Limited

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
11450.0 INR 83.00 ( 0.73%)
Last update at 2026-11-12T09:45:00Z
VOLUME
715040
Market Cap
1752225.28M
P/E
70.47

Momentum Score

…

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
11272.00
Low
11472.00
High
52 Week Price Range
4932.54
Low
7039.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
11367.00
Dividend Yield
-
Revenue TTM
100290.00M
Revenue Per Share
377.74
Gross Profit TTM
60970.00M
Debt / Equity
0.00
ROE
17.06%
Net Debt
-4280.00M
ROCE
18.84%
Diluted EPS TTM
93.66

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax 29160.00M 21630.00M 23686.30M 36835.00M 26660.40M
Minority interest 0.00M 0.00M 0.00M 0.00M 0.00M
Net income 21910.00M 16000.00M 18240.00M 29604.50M 19842.90M
Selling general administrative 1430.00M 1250.00M 1260.00M 1085.90M 831.40M
Selling and marketing expenses 1360.00M 900.00M 1140.00M 1270.10M 1240.30M
Gross profit 31910.00M 45270.00M 44870.00M 57073.50M 45342.60M
Reconciled depreciation 4020.00M 3780.00M 3431.80M 3115.10M 2555.90M
Ebit 29190.00M 21650.00M 23705.90M 36854.90M 26681.30M
Ebitda 33210.00M 25430.00M 27137.70M 39970.00M 29237.20M
Depreciation and amortization 4020.00M 3780.00M 3431.80M 3115.10M 2555.90M
Operating income 26380.00M 19520.00M 20622.10M 35737.70M 26159.90M
Other operating expenses 67200.00M 59640.00M 56866.00M 52254.60M 42423.50M
Interest expense 30.00M 30.00M 19.60M 19.90M 20.90M
Tax provision 7250.00M 5630.00M 5452.50M 7230.50M 6817.50M
Interest income 3480.00M 3010.00M 3389.70M 8.00M 52.50M
Net interest income -20.00M -30.00M -6.70M -8.00M -8.70M
Income tax expense 7250.00M 5630.00M 5452.50M 7230.50M 6817.50M
Total revenue 93580.00M 77960.00M 77488.10M 87992.30M 68583.40M
Total operating expenses 5530.00M 4610.00M 4914.10M 21335.80M 19182.70M
Cost of revenue 61670.00M 32690.00M 51951.90M 30918.80M 23240.80M
Total other income expense net 2780.00M 2110.00M 3064.20M 1097.30M 500.50M
Net income from continuing ops 21910.00M 16000.00M 18233.80M 29604.50M 19842.90M
Net income applicable to common shares 21910.00M 16000.00M 18233.80M 29604.50M 19842.90M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 169470.00M 154700.00M 144387.70M 133747.10M 107740.70M
Intangible assets 40.00M 40.00M 52.80M 74.90M 49.50M
Other current assets 650.00M 6320.00M 2017.70M 2175.50M 1531.90M
Total liab 19780.00M 18990.00M 16716.80M 16465.30M 14794.60M
Total stockholder equity 149690.00M 135710.00M 127670.90M 117281.80M 92946.10M
Other current liab 5000.00M 8950.00M 2875.60M 3990.30M -47.20M
Common stock 530.00M 530.00M 530.90M 530.90M 530.90M
Capital stock 530.00M 530.00M 530.90M 530.90M 530.90M
Retained earnings 134000.00M 117860.00M 109581.10M 99888.50M 75977.20M
Other liab - - - 4481.10M 3633.10M
Other assets 750.00M 680.00M 956.70M 1562.20M 1848.60M
Cash 4320.00M 3630.00M 1697.00M 12147.60M 20303.20M
Cash and equivalents 3940.00M 3400.00M 1407.70M 11928.80M 20085.20M
Total current liabilities 14520.00M 12780.00M 11010.80M 11955.50M 11124.60M
Current deferred revenue 400.00M 340.00M 505.20M - 3528.40M
Net debt -4280.00M -3600.00M -1664.40M -12110.70M -20254.90M
Short term debt 20.00M 20.00M 4.90M 8.20M 11.40M
Short long term debt 20.00M 0.00M 0.00M 0.00M 3.50M
Short long term debt total 40.00M 30.00M 32.60M 36.90M 48.30M
Other stockholder equity 800.00M 17060.00M 17558.90M 16862.40M 16438.00M
Property plant equipment 64600.00M 55130.00M 49292.00M 47874.90M 44095.40M
Total current assets 100810.00M 96750.00M 93117.40M 83515.00M 61747.10M
Net tangible assets - - - 117206.90M 92896.60M
Short term investments 31240.00M 33380.00M 40494.60M 15270.10M 546.40M
Net receivables 29780.00M 21580.00M 18904.00M 25635.60M 17913.30M
Inventory 33230.00M 31840.00M 30004.10M 28286.20M 21452.30M
Accounts payable 9100.00M 8240.00M 7625.10M 7957.00M 7632.00M
Accumulated other comprehensive income 14360.00M 260.00M - - -
Non currrent assets other 640.00M 1660.00M 40996.30M 16930.10M 2348.20M
Non current assets total 68660.00M 57950.00M 51270.30M 50232.10M 45993.60M
Capital lease obligations 20.00M 30.00M 32.60M 36.90M 44.80M
Long term debt total 20.00M 20.00M 27.70M 28.70M 36.90M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -8040.00M -2690.00M -27076.20M -15485.30M 9281.60M
Change to liabilities - - 0.00M 342.70M 1748.00M
Total cashflows from investing activities -10990.00M -2690.00M -27076.20M -21949.20M 751.30M
Net borrowings - - - -11.40M -340.20M
Total cash from financing activities -7970.00M -7990.00M -7971.70M -5324.40M -348.90M
Change to operating activities - - - 202.90M 1078.90M
Net income 21910.00M 16000.00M 23686.30M 36835.00M 26660.40M
Change in cash 610.00M 1930.00M -10450.60M -8155.60M 19871.70M
Begin period cash flow 3710.00M 1700.00M 12147.60M 20303.20M 431.50M
End period cash flow 4320.00M 3630.00M 1697.00M 12147.60M 20303.20M
Total cash from operating activities 19460.00M 12610.00M 24597.30M 19118.00M 19469.30M
Depreciation 4020.00M 3780.00M 3431.80M 3115.10M 2555.90M
Other cashflows from investing activities 35410.00M 3000.00M -22346.00M 668.10M 570.10M
Dividends paid -7960.00M -7960.00M 7964.10M 5309.40M 5309.40M
Change to inventory -520.00M -1840.00M -1717.90M -6833.90M -2813.70M
Change to account receivables -5820.00M -3610.00M 6504.10M -7416.20M -2653.10M
Other cashflows from financing activities -10.00M -20.00M -7.60M -15.00M -16.10M
Change to netincome - - - 102.90M -288.70M
Capital expenditures 14380.00M 10030.00M 4730.20M 7132.00M 9101.90M
Change in working capital -5540.00M -6070.00M 4188.10M -13704.50M -2640.80M
Other non cash items -930.00M -1100.00M -6708.90M -7127.60M -7106.20M
Free cash flow 5080.00M 2580.00M 19867.10M 11986.00M 10367.40M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(INR)
Price
(INR)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DIVISLAB
Divi's Laboratories Limited		 83.00
0.73%		 11450.00 70.47 - 17.47 11.44 17.33 47.08
SUNPHARMA
Sun Pharmaceutical Industries Limited		 -12.10
0.64%		 1890.20 40.32 26.95 7.69 5.50 7.41 23.64
TORNTPHARM
Torrent Pharmaceuticals Limited		 -60.90
1.28%		 4700.10 63.48 56.50 11.13 16.39 11.65 35.91
CIPLA
Cipla Limited		 -15.90
1.12%		 1404.00 21.74 19.01 4.23 3.76 4.08 14.00
DRREDDY
Dr. Reddy's Laboratories Limited		 11.00
0.80%		 1388.00 17.16 21.93 2.94 2.89 2.99 10.39

Profile*

Divi's Laboratories Limited

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Divi Towers, Hyderabad, India, 500032

91 40 6696 6300

https://www.divislabs.com

10542

Name Title Year Born
Dr. Kiran Satchandra Divi B. Pharm., M.Pharm CEO & Whole-Time Director 1976
Mr. L. Kishore Babu B.Com, FCMA, FICWA Chief Financial Officer 1952
Mr. L. Ramesh Babu LLB, M.Com, MBA VP of Procurement & Chief Information Officer 1957
Mr. M. Satish Choudhury Company Sec. & Compliance Officer NA
Mr. Venkata Ramana Nimmagadda B.Sc.(Chem) Exec. Director 1958
Dr. Murali Krishna Prasad Divi M. Pharm, Ph.D. MD & Exec. Director 1951
Mr. Madhusudana Rao Divi Director of Projects & Whole-Time Director 1944
Mr. M. Ramesh Babu B.Sc. Chief Technologist 1966
Mr. P. Srinivasa Rao M.Pharm Chief Technologist 1965
Ms. Nilima Prasad Divi Whole-time Director & Director of Commercial 1982

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…